Extracted Trials
Select a trial for this version to view the audit.
NCT03302234
KEYNOTE-598Boyer et al. (2021)
Eligibility Criteria
Inclusion Criteria
Has a histologically or cytologically confirmed diagnosis of Stage IV metastatic non-small cell lung cancer (NSCLC) ... Must agree to use contraception ...
Exclusion Criteria
Has received prior systemic chemotherapy ... Has a tumor that harbors EGFR-sensitizing mutation or ALK translocation ... Is currently participating in or has participated in a trial of an investigational agent ... Has received prior therapy with an anti-PD-1 ... Has known untreated CNS metastases ... Has an active autoimmune disease ... Is pregnant or breastfeeding ... Has severe hypersensitivity to pembrolizumab and/or ipilimumab ...
Bibliographic Info
- Trial Acronym:
- KEYNOTE-598
- First Author:
- Boyer
- Year:
- 2021
- PMID:
- 33513313
Patient Baseline
- N (Intervention):
- 284
- N (Control):
- 284
Intervention Details